RBC Capital Highlights BeOne Medicines' (ONC) Rich Pipeline

RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $311.00 price target on BeOne Medicines (NASDAQ: ONC).

The analyst commented: "Rich Pipeline Can Drive The Next Leg Of Growth After Near-Term Heme-Onc Execution; We attended ONC's R&D Day focused on the hematology and solid tumor portfolio and had a chance to catch up with mgmt. Investors had been focused on the CDK4i program heading into today, and while updates had more limited data that may need time to mature, we think ONC has shown enough to suggest a differentiated safety profile with efficacy that can deepen to competitive levels; meanwhile the rest of the pipeline continues to show solid progress. We continue to like shares given Brukinsa's growth potential ($3.7B in '25E sales growing to $6.7B by 2034E), near-term potential of sonro and '673 to drive further CLL growth, and believe the pipeline gives us confidence that ONC can successfully evolve into a diversified oncology powerhouse over the next decade."

For an analyst ratings summary and ratings history on BeOne Medicines click here. For more ratings news on BeOne Medicines click here.

Shares of BeOne Medicines closed at $254.49 yesterday.

You May Also Be Interested In

• Chevron signed an agreement with Iraq's Basra Oil Company to advance commercial negotiations for West Qurna 2
• Energy Vault Holdings (NRGV) files $300M mixed shelf
• Uber (UBER) Reiterated at Market Outperform by Citizens on Delivery Hero Deal